12:00 AM
Nov 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SA-IGIV: Began Phase I/II trial

Inhibitex Inc., Alpharetta, Ga.
Product: SA- IGIV
Business: Infectious diseases
Therapeutic category: Bacterial infection
Target: MSCRAMMs
Description: Antibody-based...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >